参考文献/References:
[1]Wee CY,Yap PT,Zhang D,et al.Identification of MCI individuals using structural and funtional connectivity networks[J].Neuroimage,2012,59(3):2045-2056. [2]Sharma P,Srivastava P,Seth A,et al.Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies[J].Prog Neurobiol,2018(174):53-89. [3]Pannee J,Portelius E,Minthon L,et al.Referencemensurement procedure for CSF amyloid beta(Aβ)1-42 and the Aβ1-42 /Aβ1-40 ratio across valiadation study againstamyloid PET[J].J Neurochem,2016,139(4):651-658. [4]Grimmer T,Riemenschneider MF,Rstl H,et al.Beta amyloid in Alzheimer’s disease increase deposition in brain is reflected in reduced concentration in cerebrospinal fluid[J].Biol Psychiatry,2009,65(11):927-934. [5]Ewers M,Mattsson N,Minthon L,et al.CSF biomarkers for the differential diagnosis of Alzheimer’s disease:a large-scale international multicenter study[J].Alzheimer’s Dement,2015(11):1306-1315. [6]Lewczuk P,Matzen A,Blennow K,et al.Cerebrospinal fluid Aβ42/40 corresponds better than Aβ42 to amyloid PET in Alzheimer’s disease[J].J Alzheimers Dis,2017(55):813-822. [7]Roberson ED,Screarce-Levie K,Palop JJ,et al.Reducing endogenous tau ameliorates amyloid beta induced deficits in an Alzheimer’s disease mouse model[J].Biol Science,2007,316(5825):750-754. [8]Anoop A,Singh PK,Jacob RS,et al.CSF Biomarkers for Alzheimer’s disease Diagnosis[J].Inte J Alzheimer’s Dis,2010(13):1727-1732. [9]Vacante M,Smallagc N,Sachpekidis C,et al.The accuracy of 18 FDG-PET in the early diagnosis of Alzheimer’s disease dementia and other dementias in people with MCI[J].Cochrane Database Syst Rev,2015(28):CD010632. [10]Blennow K,Zetterberg H.Biomarkers for Alzheimer’s disease:current status and prospects for the future[J].Intern Med,2018,284(6):643-663. [11]Olsson B,Lautner R,Andreasson U,et al.CSF and blood biomarkers for the diagnosis of Alzheimer’s disease:a systematic review and meta-analysis[J].Lancet Neurol,2016,15(7):673-684. [12]Mattsson N,Zetterberg H,Janelidze S,et al.Plasma tau in Alzheimer’s disease[J].Neurology,2016(87):1827-1835. [13]Kvartsberg H,Duits FH,Ingelsson M,et al.Cerebrospinal fluidlevels of the synaptic protein neurogranincorre-lates with cognitive decline in prodromal Alzheimer’s disease[J].Alzheimers Dement,2015,11(10):1180-1190. [14]Hellwig K,Kvartsberg H,Portelius E,et al.Neurogranin andYKL-40:independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s dis-ease[J].Alzheimers Res Ther,2015(7):74. [15]Wellington H,Paterson RW,Portelius E,et al.Increased CSFneurogranin concentration is specific to Alzheimer’s disease[J].Neurology,2016,86(9):829-835. [16]Yuan A,Rao MV,Veeranna Nixon RA.Neurofilaments at a glance[J].J Cell Sci,2012(125):3257-3263. [17]Yuan A,Rao MV,Veeranna,et al.Neurofilaments and Neurofilament Proteins in Health and Disease[J].Cold Spring Harb Perspect Biol,2017,9(4):a018309. [18]Skillback T,Farahmand B,Bartlett JW,et al.CSF neuroflament light differs in neurodegenerative diseases and predictsseverity and survival[J].Neurology,2014(83):1945-1953. [19]Weston PSJ,Poole T,Ryan NS,et al.Serum neurofilament light in familial Alzheimer disease:a marker of early neurodegeneration[J].Neurology,2017,89(21):2167-2175. [20]Lee JM,Blennow K,Andreasen N,et al.The brain injury biomarker VLP-1 is increased inthe cerebrospinal fuid of Alzheimer disease patients[J].Clin Chem,2008(54):1617-1623. [21]Sutphen CL,McCue L,Herries EM,et al.Longitudinal decreases in multiplecerebrospinalfuid biomarkers of neuronal injury in symptomaticlate onset Alzheimer’s disease[J].AlzheimersDement,2018(14):869. [22]Tarawneh R,D’Angelo G,Macy E,et al.Visinin-like protein-1:diagnostic and prognostic biomarker in Alzheimer disease[J].Ann Neurol,2011(70):274-285. [23]Jay TR,von Saucken VE,Landreth GE.TREM2 in neurodegenerative diseases[J].Mol Neurodegener,2017,12(1):56. [24]Brosseron F,Traschutz A,Widmann CN,et al.Characterization and clinical use of infammatory cerebrospinal fuid protein markers in Alzheimer’sdisease[J].Alzheimers Res Ther,2018,10(1):25. [25]Heslegrave A,Heywood W,Paterson R,et al.Increased cerebrospinal fuid soluble TREM2 concentration in Alzheimer’s disease[J].Mol Neurodegener,2016(11):3 [26]Henjum K,Almdahl IS,Arskog V,et al.Cerebrospinal fuid soluble TREM2 in aging and Alzheimer’s disease[J].Alzheimers Res Ther,2016,8(1):17.
相似文献/References:
[1]刘 璐,秦新月.阿尔茨海默病患者血尿酸水平变化的研究[J].医学信息,2018,31(02):96.[doi:10.3969/j.issn.1006-1959.2018.02.033]
LIU Lu,QIN Xin-yue.Study on the Changes of Serum Uric Acid in Alzheimer 's Disease Patients[J].Medical Information,2018,31(14):96.[doi:10.3969/j.issn.1006-1959.2018.02.033]
[2]赖 超,成官迅.rs-fMRI、DTI及1H-MRS在阿尔茨海默病中的应用进展[J].医学信息,2018,31(13):41.[doi:10.3969/j.issn.1006-1959.2018.13.013]
LAI Chao,CHENG Guan-xun.Application of rs-fMRI、DTI and 1H-MRS in Alzheimer’s Disease[J].Medical Information,2018,31(14):41.[doi:10.3969/j.issn.1006-1959.2018.13.013]
[3]唐娟娟,高春岭,秦凤琴.蒙特利尔认知评估量表在成都市郫都区老年性痴呆筛查中的应用分析[J].医学信息,2018,31(19):12.[doi:10.3969/j.issn.1006-1959.2018.19.004]
TANG Juan-juan,GAO Chun-ling,QIN Feng-qin.Application Analysis of Montreal Cognitive Assessment Scale in Screening for Alzheimer’s Disease in Pidu District,Chengdu[J].Medical Information,2018,31(14):12.[doi:10.3969/j.issn.1006-1959.2018.19.004]
[4]杨联勇,沈金娥.阿尔茨海默病新药的临床实验研究[J].医学信息,2020,33(02):50.[doi:10.3969/j.issn.1006-1959.2020.02.014]
YANG Lian-yong,SHEN Jin-e.Clinical Experimental Study of New Drugs for Alzheimer’s Disease[J].Medical Information,2020,33(14):50.[doi:10.3969/j.issn.1006-1959.2020.02.014]
[5]姜凤全,王 琪,曹胜吉,等.XT-4000i血细胞分析仪在脑脊液白细胞计数及分类计数中的应用[J].医学信息,2020,33(21):82.[doi:10.3969/j.issn.1006-1959.2020.21.024]
JIANG Feng-quan,WANF Qi,CAO Sheng-ji,et al.The Application of XT-4000i Blood Cell Analyzer in Cerebrospinal Fluid White Blood Cell Count and Classification Count[J].Medical Information,2020,33(14):82.[doi:10.3969/j.issn.1006-1959.2020.21.024]
[6]康晨瑶,刘 洲,周海红.NLRP3炎症小体在AD发病机制中的作用[J].医学信息,2021,34(12):40.[doi:10.3969/j.issn.1006-1959.2021.12.011]
KANG Chen-yao,LIU Zhou,ZHOU Hai-hong.The Role of NLRP3 Inflammasome in the Pathogenesis of AD[J].Medical Information,2021,34(14):40.[doi:10.3969/j.issn.1006-1959.2021.12.011]
[7]张 瑞,延沁儒.丹酚酸B调节Bax/Bcl-2的表达对阿尔茨海默病小鼠认知功能的影响及机制[J].医学信息,2021,34(17):70.[doi:10.3969/j.issn.1006-1959.2021.17.018]
ZHANG Rui,YAN Qin-ru.Effects of Salvianolic Acid B on the Cognitive Function of Alzheimer’s Disease Mice and its Mechanism Regulating the Expression of Bax/Bcl-2[J].Medical Information,2021,34(14):70.[doi:10.3969/j.issn.1006-1959.2021.17.018]
[8]张 辉,张 颖.多奈哌齐联合司来吉兰对阿尔茨海默病患者认知功能及不良反应的影响[J].医学信息,2022,35(13):110.[doi:10.3969/j.issn.1006-1959.2022.13.024]
ZHANG Hui,ZHANG Ying.Effect of Donepezil Combined with Selegilan on Cognitive Function and Adverse Reactions in Patients with Alzheimer’s Disease[J].Medical Information,2022,35(14):110.[doi:10.3969/j.issn.1006-1959.2022.13.024]
[9]于京虎.复方脑肽节苷脂联合多奈哌齐对阿尔茨海默病患者认知功能及SOD水平的影响[J].医学信息,2023,36(03):148.[doi:10.3969/j.issn.1006-1959.2023.03.031]
YU Jing-hu.Effect of Compound Porcine Cerebroside and Ganglioside Combined with Donepezil on Cognitive Function and SOD Level in Patients with Alzheimer’s Disease[J].Medical Information,2023,36(14):148.[doi:10.3969/j.issn.1006-1959.2023.03.031]
[10]徐 静.综合康复护理对阿尔兹海默病患者认知功能及生活能力的影响[J].医学信息,2023,36(04):150.[doi:10.3969/j.issn.1006-1959.2023.04.031]
XU Jing.Effect of Comprehensive Rehabilitation Nursing on Cognitive Function and Living Ability of Patients with Alzheimer’s Disease[J].Medical Information,2023,36(14):150.[doi:10.3969/j.issn.1006-1959.2023.04.031]